It’s been about a month since the Trump Administration signed an Executive Order reviving the Most Favored Nation (MFN) concept and now the industry is facing what could be one of the most consequential pricing policy shifts in decades.

Marbls partners with pharmaceutical and medical device and diagnostic manufacturers to provide practical, innovative services that address complex pricing, contracting and commercial excellence needs — driving the path of critical drugs, devices, and diagnostics to market. We invest in the long-term success of our clients by investing in our employees. As a team with world-class experience and a client-first philosophy, we create long term relationships based on success, service and trust. Our approach is results driven, hands-on and flexible to address the unique internal and external dynamics impacting our clients.